November 21, 2026 / Care,Clinical Trials,Research

FDA Issues Complete Response Letter for Deramiocel

Today, the FDA announced that it has issued a Complete Response Letter (CRL) for Capricor Therapeutics’ Biologics License Application (BLA) for Deramiocel (CAP-1002), the company’s cell therapy for Duchenne cardiomyopathy. This decision is devastating and means that the current application will not be approved. 

This is heartbreaking news for the Duchenne community, particularly for individuals and families that have sacrificed years of their time through trial participation and those who have followed Deramiocel’s development and have been waiting for a regulatory decision. While a CRL means the current application will not be approved, it does not necessarily mean that Deramiocel cannot ultimately receive FDA approval.

However, in its November 20, 2026, statement, the FDA identified concerns regarding “serious clinical trial data integrity deficiencies identified in Study HOPE-3 that the agency has determined render the study data unreliable and incapable of post hoc remediation”. Specifically, the agency pointed to issues including:

  • Unauthorized post hoc changes to the statistical analysis plan,
  • Violations of study blinding procedures,
  • And additional protocol violations that, individually and collectively, compromise the reliability of the study data.

According to the FDA, the agency’s Bioresearch Monitoring (BIMO) Program also conducted an inspection of Capricor in connection with the company’s BLA, and identified serious deficiencies in the conduct of Study HOPE-3. The agency issued a Regulatory Responsibility Letter (RRL), and Capricor will now have the opportunity to address the issues in the RRL.

What’s Next?

We understand that individuals currently participating in clinical trials or receiving Deramiocel through other authorized programs will have immediate questions about continued access and what this decision means for their care. A CRL does not, by itself, establish whether ongoing clinical trials or other treatment access programs will continue. Decisions regarding ongoing treatment, clinical trial participation, and access programs will require additional information from Capricor and the FDA. 

According to Capricor, the company is reviewing the CRL carefully and will share next steps once they have completed their evaluation. The company will hold a conference call and webcast on Monday, November 23, 2026, at 8:30 a.m. ET. Read Capricor’s press release here.

Individuals and families currently participating in a Deramiocel study should contact their study team or treating clinician for information specific to their circumstances.

PPMD will seek clarification about the implications for ongoing study participants and share information with the community as it becomes available. We remain resolute in our mission to bring potentially safe and effective therapies to this community and will partner with both Capricor and the FDA in order to support a path forward . 

While this decision represents a heartbreaking setback, it does not yet mark the end of the road. Together, we will keep driving progress forward.

Join Our Mailing List

This field is for validation purposes and should be left unchanged.
BBB Accredited Charity logoCharity Navigator Four Star Charity logoNational Health Council Standards of Excellence Certification Program logo